Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

Executive Summary

• Medicenna Therapeutics announced that updated pre‑clinical data for MDNA113, its first‑in‑class PD‑1 × IL‑2 bifunctional Superkine, will be presented at the AACR 2026 Annual Meeting (April 21, 2026).
• The presentation will showcase in‑vivo animal efficacy, tumor selectivity, and safety data from non‑human primate studies, underscoring MDNA113’s differentiated therapeutic profile.
• MDNA113 is advancing toward an IND submission in the second half of 2026 for solid tumors that overexpress IL‑13Rα2 (e.g., pancreatic, liver, brain, breast, colon, ovarian, prostate).

Key Details

• Product Overview: MDNA113 is a “masked” tumor‑targeted anti‑PD‑1‑IL‑2 Superkine designed to be conditionally activated by metalloproteases in the tumor microenvironment (TME) and anchored at IL‑13Rα2‑expressing sites.
• Target Indication Space: Over 2 million patients worldwide with “immunologically cold” solid tumors that have high unmet need.
• Pre‑clinical Highlights to be Presented:
• Exceptional tumor selectivity and localization demonstrated in vivo.
• Potent anti‑tumor activity with improved systemic tolerability versus unmasked PD‑1/IL‑2 combos.
• Immunodynamic readouts and safety signals from non‑human primate studies indicating a differentiated profile.
• Conference Presentation Details:
• Title: “MDNA113 is a masked conditionally activated tumor‑targeted anti‑PD1‑IL‑2SK with superior safety and therapeutic properties.”
• Session: Monoclonal Antibodies and Antibody‑Cytokine Platforms.
• Date/Time: Tuesday, April 21, 2026; 9:00 AM – 12:00 PM.
• Location: Poster Section 9, Board 13, Abstract #4342.
• Regulatory Timeline: IND filing planned for H2 2026.
• Company Context: Medicenna is also developing MDNA11 (long‑acting IL‑2 Superkine) and bizaxofusp (IL‑4 Empowered Superkine), the latter with Fast Track and Orphan Drug designations.

Notable Quotes

(No direct quotes were provided in the release.)